The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort

Basit Öğe Kaydı
dc.contributor.authorYaraş, Serkan
dc.contributor.authorDemir, Mehmet
dc.contributor.authorBarutcu, Sezgin
dc.contributor.authorYıldırım, Abdullah Emre
dc.contributor.authorGürel, Selim
dc.contributor.authorUçbilek, Enver
dc.contributor.authorAkgün Kurtulmus, İlkce
dc.date.accessioned2024-08-25T18:45:30Z
dc.date.available2024-08-25T18:45:30Z
dc.date.issued2023
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground and Aim: The aims of the present study were to evaluate the real-life efficacy and tolerability of glecaprevir (GLE)/pibrentasvir (PIB) in the treatment of patients with chronic hepatitis C (CHC). Materials and Methods: Between May 2019 and May 2022, 686 patients with CHC, treated with GLE/PIB combination from 21 participating centers in Turkiye, were enrolled in the study.Results: All patients were Caucasian, and their median age was 56 years. At the start of GLE/PIB treatment, the median serum Hepatitis C virus RNA and serum alanine amino transaminase (ALT) levels were 6.74 log10 IU/mL and 47 U/L, respectively. Fifty-three percent of the patients were infected with genotype 1b, followed by genotype 3 (17%). Diabetes was the more common concomitant disease. The sustained virological response (SVR12) was 91.4% with intent-to-treat analysis and 98.5% with per protocol analysis. The SVR12 rates were statistically significant differences between the patients who were i.v. drug users and non-user (88.0% vs. 98.8%, p=0.025). From the baseline to SVR12, the serum ALT levels and Model for End-Stage Liver Disease score were significantly improved (p<0.001 and p=0.014, respectively). No severe adverse effect was observed.Conclusion: GLE/PIB is an effective and tolerable treatment in patients with CHC.en_US
dc.identifier.doi10.14744/hf.2023.2023.0001-2
dc.identifier.endpage96en_US
dc.identifier.issn1307-5888
dc.identifier.issn2757-7392
dc.identifier.issue3en_US
dc.identifier.startpage92en_US
dc.identifier.urihttps://doi.org/10.14744/hf.2023.2023.0001-2
dc.identifier.urihttps://hdl.handle.net/11454/101589
dc.identifier.volume4en_US
dc.identifier.wosWOS:001109338900001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherKare Publen_US
dc.relation.ispartofHepatology Forumen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240825_Gen_US
dc.subjectChronic hepatitis Cen_US
dc.subjectglecaprevir-pibrentasviren_US
dc.subjectreal-life experienceen_US
dc.subjectInjecting Drug-Useen_US
dc.subjectPeopleen_US
dc.subjectHiven_US
dc.titleThe efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohorten_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu